IL1B and COVID-19: Use of baricitinib (4 mg twice/die for 2 days and after 4 mg/die for 7 days) in hospitalized COVID-19 patients (n = 20), decreased serum levels of both IL-1β and IL-6 and moreover, increased the P/F ratio decreasing need of oxygen therapy as compared to hospitalized COVID-19 (n = 56) treated with standard care [224].